

Atty. Dkt. No. 041673-0301

REMARKS

With this amendment, Claims 1 and 10-12 are now pending; Claim 2 is canceled; and Claims 3-9 are withdrawn, without prejudice.

Claims 10-12 are new. No new matter is added by their addition to the application, in that each is supported, for example, by the text of Example 1. Entry of the proposed amendments, including new claims 10 -12, is therefore requested.

The Examiner has required restriction between Claims 1-2, drawn to a nucleic acid encoding a lysophospholipid-specific human brain lysophospholipase (hLSL) (Group I); Claims 2-4, drawn to the hLSL polypeptide (Group II); Claims 5-6, drawn to a method for inhibiting the catalytic activity of an hLSL enzyme (Group III); Claims 7-8, drawn to a method of treating a patient against diseases caused by increased levels of lysophospholipase (Group IV); and Claim 9, drawn to a method for gene therapy (Group V). Election of Group I without traverse is made only for the purposes of expediting allowance of Claims 1 and 2, and is not intended as an admission that the restriction requirement is proper.


Applicants believe that the claims are now in condition for allowance. Favorable consideration of Claims 1 and 10-12 is hereby requested.

Respectfully submitted,

Date

4 - 4 - 2006

By



FOLEY & LARDNER LLP
Customer Number: 30542
Telephone: (858) 847-6720
Facsimile: (858) 792-6773

Stacy L. Taylor
Attorney for Applicant
Registration No. 34,842